We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-0.73%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$841M
AUM Growth
-$257M
Cap. Flow
+$27.7M
Cap. Flow %
3.29%
Top 10 Hldgs %
71.13%
Holding
232
New
70
Increased
34
Reduced
47
Closed
75

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$56.8M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$12.1M
3
COGT icon
Cogent Biosciences
COGT
+$9.38M
4
INCY icon
Incyte
INCY
+$7.38M
5
NKTR icon
Nektar Therapeutics
NKTR
+$3.34M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$58.4M
2
ESPR
Esperion Therapeutics
ESPR
+$9.06M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$6.4M
4
MNKD icon
MannKind Corp
MNKD
+$3.35M
5
ABBV icon
AbbVie
ABBV
+$3.03M

Sector Composition

Rank Sector Weight
1 Miscellaneous 83.05%
2 Healthcare 16.08%
3 Consumer Staples 0.43%
4 Consumer Discretionary 0.12%
5 Materials 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RGNX icon
176
CALL
Regenxbio
RGNX
$574M
– –
-81
Closed -$269K
SAGE
177
CALL
DELISTED
Sage Therapeutics
SAGE
– –
-350
Closed -$5.76M
SAGE
178
PUT
DELISTED
Sage Therapeutics
SAGE
– –
-259
Closed -$4.27M
SPY icon
179
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$803B
– –
-3,000
Closed -$53.6M
TNDM icon
180
Tandem Diabetes Care
TNDM
$1.17B
– –
-27,487
Closed -$65K
VRTX icon
181
PUT
Vertex Pharmaceuticals
VRTX
$132B
– –
-486
Closed -$7.28M
VTVT icon
182
vTv Therapeutics
VTVT
$126M
– –
-1,113
Closed -$267K
XNTK icon
183
CALL
State Street SPDR NYSE Technology ETF
XNTK
$1.87B
– –
-656
Closed -$5.57M
CSCI
184
CALL
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
– –
-1
Closed -$33K
CSCI
185
PUT
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
– –
-3
Closed -$46K
ORKA
186
Oruka Therapeutics
ORKA
$6.12B
– –
-463
Closed -$138K
VIRX
187
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-3,571
Closed -$612K
KA
188
DELISTED
Kineta, Inc. Common Stock
KA
– –
-429
Closed -$350K
SCPX
189
DELISTED
Scorpius Holdings, Inc.
SCPX
– –
-9
Closed -$1M
YTEN
190
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
– –
-224
Closed -$381K
ICPT
191
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-447
Closed -$2.61M
CGRN
192
DELISTED
Capstone Green Energy Corporation Common Stock
CGRN
– –
-98,379
Closed -$758K
ACGN
193
DELISTED
Aceragen Inc
ACGN
– –
-283
Closed -$650K
SIOX
194
CALL
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-268
Closed -$1.13M
SIOX
195
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-14,433
Closed -$608K
SIOX
196
PUT
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-231
Closed -$974K
CLVS
197
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-67
Closed -$456K
TMBR
198
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
– –
-448
Closed -$740K
RDUS
199
CALL
DELISTED
Radius Health, Inc.
RDUS
– –
-1,536
Closed -$4.88M
ADXS
200
CALL
DELISTED
Advaxis Inc
ADXS
– –
-18
Closed -$77K
6 7
8
9 10

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q1 2018 Portfolio in Review

As of Q1 2018, Sabby Management held 232 positions worth $841M, down 23% from $1.1B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Sabby Management deployed $27.7M of net new capital in Q1 2018, opening 70 new positions and adding to 34 existing holdings. Its largest new stake was Biogen: 182,898 shares worth $50.1M.

By sector, the portfolio is most concentrated in Miscellaneous at 83% of assets, down from 87% a quarter earlier, followed by Healthcare and Consumer Staples.

On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $58.4M trimmed.

  • Sabby Management's largest Q1 2018 buy was Biogen: 182,898 shares worth $50.1M.
  • Sabby Management added most to Nektar Therapeutics in Q1 2018, an estimated $3.34M increase.
  • Sabby Management's biggest Q1 2018 reduction was Bristol-Myers Squibb, cutting an estimated $58.4M.
  • Sabby Management fully exited Spark Therapeutics, Inc. Common Stock in Q1 2018, selling an estimated $6.4M.
  • Sabby Management's ten largest holdings make up 71% of its $841M portfolio in Q1 2018.
  • Sabby Management opened 70 new positions and closed 75 in Q1 2018.
  • Sabby Management's portfolio value fell 23% quarter-over-quarter to $841M.

Based on Sabby Management's 13F filing for Q1 2018, filed 15 May 2018.